Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共4页
• 作者

  Ryan Daniel H.; Uy Geoffrey L.; Cortes Jorge E.; Newell Laura F.; Ritchie Ellen K.; Stuart Robert K.; Strickland Stephen A.; Hogge Donna; Solomon Scott R.; Stone Richard M.; Bixby Dale L.; Kolitz Jonathan E.; Schiller Gary J.; Wieduwilt Matthew J.; Ryan Robert; Chiarella Michael; Louie Arthur C.; Lancet Jeffrey E.;

  展开▼
• 作者单位

  Univ Rochester Victor NY USA;

  Washington Univ Sch Med St Louis MO USA;

  Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

  Oregon Hlth &

  Sci Univ Portland OR 97201 USA;

  Cornell Univ Weill Cornell Med New York NY 10021 USA;

  Med Univ South Carolina Hollings Canc Ctr Charleston SC 29425 USA;

  Vanderbilt Ingram Canc Ctr Nashville TN USA;

  Leukemia BMT Program British Columbia Vancouver BC Canada;

  Northside Hosp Canc Ctr Inst Leukemia Program Atlanta GA USA;

  Dana Farber Canc Inst Boston MA 02115 USA;

  Univ Michigan Ctr Comprehens Canc Grass Lake MI USA;

  Northwell Hlth Monter Canc Ctr Lake Success NY USA;

  Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;

  Univ Calif San Diego Moores Canc Ctr San Diego CA 92103 USA;

  Jazz Pharmaceut Palo Alto CA USA;

  Jazz Pharmaceut Palo Alto CA USA;

  Jazz Pharmaceut Palo Alto CA USA;

  H Lee Moffitt Canc Ctr &

  Res Inst Tampa FL USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词